ExpreS2ion announces formation of Infectious Diseases Scientific Advisory Board
Hørsholm, Denmark, March 9, 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces the establishment of an Infectious Diseases Scientific Advisory Board (ISAB). The four initial members of the ExpreS2ion ISAB bring a depth of knowledge in infectious diseases, clinical trials and preventive vaccines, and will contribute to the development of ExpreS2ion’s proprietary pipeline efforts in the infectious diseases field. The ISAB will serve as advisors and participants in key opinion leader events for the scientific community and investors.
Chief Executive Officer Bent Frandsen comments:
“I am very pleased to announce the establishment of our ISAB, comprised of four renowned Key Opinion Leaders who will support our pipeline efforts in the Infectious Disease field. On behalf of ExpreS2ion, I welcome our new ISAB members to join our continued journey, and I look forward to including their valuable input in our development of novel vaccines that will potentially benefit in the prevention of infectious disease worldwide.”
Chief Medical Officer Mattis Flyvholm Ranthe comments:
“This team of experts brings unique, varied and best-in-class specialists together, providing critical input to ExpreS2ion’s non-clinical and clinical development programs of our vaccine candidates within infectious diseases. Our ISAB members will provide expert input across the spectrum of pre-clinical development, such as antigen selection and cutting-edge in vivo models. This is another huge step forward for ExpreS2ion, supplementing our in-house competencies.”
Chief Scientific Officer Farshad Guirakhoo comments:
“I am extremely pleased to be able to work with our new ISAB members, especially Stanley and Mark whom I have been fortunate to collaborate with on various projects during the last decade. Both Stanley and Mark bring enormous experience in translational and clinical vaccine development for numerous infectious diseases, particularly in the field of CMV vaccines, which will be instrumental as we aim for a speedy transition of our potential upcoming novel CMV vaccine candidates into the clinical phase.”
The inaugural members of the ExpreS2ion’s ISAB
Dr. Stanley Plotkin, MD, PhD
Dr. Stanley Plotkin serves as a consultant to the vaccine industry and is an emeritus professor at both the Wistar Institute and University of Pennsylvania, USA. He has more than 50 years of vaccine development experience. He developed the rubella vaccine, which is now used worldwide, and has played a pivotal role in both the development and application of various other vaccines including polio, rabies, varicella, rotavirus and cytomegalovirus. He is the author of more than 800 research papers.
Dr. Lone Graff Stensballe, MD, PhD
Professor at University of Copenhagen, Department of Clinical Medicine, and expert in paediatric infectious disease. Consultant in pediatrics at Department of Children and Adolescents at Copenhagen University Hospital, Rigshospitalet, Denmark. 10 years of sponsor experience with large, randomized phase 3 and 4 vaccine trials in children recruiting 11,000 Danish infants. Dr. Stensballe has (co-)authored 78 peer reviewed scientific papers.
Dr. Allan Randrup Thomsen, MD, PhD
Professor Allan Randrup Thomsen is an expert in the immune defense against viral infections and the impact of the immune response on the course of viral infections. He has more than 40 years of experience in the field and is a renowned advisor at many levels. He heads a research group in Experimental Virology at the Faculty of Health and Medical Sciences that studies how the immune system controls viral infections. Additionally, the researchers investigate how the individual maintains his/her ability to resist a re-infection.
Dr. Mark Schleiss, MD, PhD
Mark R. Schleiss, MD, is a Professor of Pediatrics in the University of Minnesota Medical School. Received his MD degree from the Oregon Health and Sciences University. Residency at Doernbecher Children's Hospital, Oregon Health and Sciences University, and his Pediatric Infectious Diseases fellowship at Seattle Children's Hospital/Medical Center. Fellowship in Molecular Medicine studying cytomegalovirus (CMV) molecular genetics at the Fred Hutchinson Cancer Research Center. His work in basic, translational and clinical research related to CMV is described at cmv.umn.edu.
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.
Tags:
